Clinical obstetric use of arachidonic acid metabolites and potential adverse effects.
D000028:Abortion, Induced; D001095:Arachidonic Acids / Q000009:adverse effects*; D002584:Cervix Uteri / Q000187:drug effects; D015237:Dinoprost / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007751:Labor, Induced; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D006473:Postpartum Hemorrhage / Q000188:drug therapy; D011247:Pregnancy; D011453:Prostaglandins / Q000009:adverse effects*; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects; D013329:Structure-Activity Relationship; D014590:Uterine Contraction / Q000187:drug effects*; D014597:Uterine Rupture / Q000139:chemically induced
D001095:Arachidonic Acids; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; C041156:prostaglandin F2 methyl ester; D015237:Dinoprost